Ormeloxifene

Ormeloxifene, commercially known as Saheli, Chhaya, Novex-DS, Centron, and Sevista, is a selective estrogen receptor modulator (SERM). This medication interacts with the estrogen receptor, serving a unique role in the world of birth control. Uniquely, it's a nonsteroidal oral contraceptive that is typically taken once per week.

Pharmacology and Mode of Action

Ormeloxifene functions as a SERM, which implies that it has selective agonistic and antagonistic activity on estrogen receptors in different tissues. Its unique mechanism involves its ability to prevent implantation by keeping the endometrium in a proliferative phase, making it unsuitable for implantation of a fertilized egg. Furthermore, it can inhibit the release of gonadotropins, which also contributes to its contraceptive effects.

Use and Efficacy

Ormeloxifene is primarily used as a contraceptive but can also be used to manage menorrhagia (excessive menstrual bleeding), and dysmenorrhea (painful periods). Despite being taken only once per week, studies suggest that it's as effective as daily oral contraceptives in preventing pregnancy when used correctly and consistently.

Availability

This medication has been available in India since the early 1990s and is currently provided free-of-cost to women under the trade name Chhaya (Centchroman). The drug has also been made available under the trade names Novex-DS, Centron, and Sevista.

Safety and Side Effects

Ormeloxifene is generally well-tolerated. Side effects can include mild weight gain, nausea, leg cramps, and minor menstrual irregularities, but these typically resolve over time. As with all contraceptives, it is not effective against sexually transmitted infections.

References

• Ormeloxifene – A selective estrogen receptor modulator
• Phase III clinical trial with Centchroman
• Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings

Ormeloxifene Resources
Latest articles Most recent articles Ongoing trials	Wikipedia